Table 2.
Effectiveness outcomes: OS, PFS, and TTF.
| Study |
n
|
Median 1L OS, mo |
Median 1L PFS, mo |
Median TTF, mo |
|||||
|---|---|---|---|---|---|---|---|---|---|
| nab-P/G | FFX | nab-P/G | FFX | p value | nab-P/G | FFX | nab-P/G | FFX | |
| mPC studies | |||||||||
| Beyer16 | 19 | 57 | 7 | 12 | NR | NR | NR | NR | NR |
| Park17 | 18 | 9 | 6.1 | 9.9 | NR | NR | NR | NR | NR |
| Braiteh20 | 122 | 80 | 8.6a | 8.6a | 0.53 | NR | NR | 3.4b | 3.8b |
| Caponnetto21 | 20 | 23 | NR | NR | NR | 6 | 5 | NR | NR |
| Kim22 | 182 | 163 | NR | NR | NR | NR | NR | 4.3b | 2.8b |
| Mañes-Sevilla23 | 20 | 15 | 9.2 | 11.4 | 0.41 | 5.4 | 7.1 | NR | NR |
| McBride24 | 294 | 256 | NR | NR | NR | NR | NR | 3.8b | 4b |
| Watanabe25c | 65 | 70 | 14.0 | 11.5 | NR | 6.5 | 5.7 | NR | NR |
| Barrera26 | 31 | 44 | 8.1 | 9.9 | 0.09 | 4.6 | 5.8 | NR | NR |
| Cartwright27 | 255 | 159 | 9.8d | 11.4d | 0.38 | NR | NR | 3.7e | 4.3e |
| Cho28 | 81 | 86 | 12.1 | 10.7 | 0.16 | 8.4 | 8.0 | NR | NR |
| Kang29 | 149 | 159f | 11.4 | 9.6 | 0.002 | 6.8 | 5.0 | NR | NR |
| Kim30 | 337 | 317 | 12.1g | 13.8g | 0.28 | NR | NR | NR | NR |
| Pacheco-Barcia31c | 25 | 21 | 7 | 14 | 0.02 | 4 | 8 | NR | NR |
| Vivaldi32c | 57 | 81 | 10.6 | 11.5 | NR | 6.2 | 6.4 | NR | NR |
| Barrera33 | 60 | 66 | NR | NR | NR | 5.5 | 5.1 | NR | NR |
| Henkel34 | 11 | 9 | 7.1 | 8.6 | NR | NR | NR | NR | NR |
| Javed35 | 81 | 204 | 7.9 | 9.9 | NR | NR | NR | NR | NR |
| aPC studiesh | |||||||||
| Cherniawsky36 | NR | NR | 10 | 11 | NR | 6.9 | 8.8 | NR | NR |
| Kasi37 | 47 | 107 | 10.8 | 15.9 | 0.17 | 5.7 | 11.7 | NR | NR |
| Maeda38 | 9 | 16 | 11.5 | 13.1 | NR | 6.1 | 6.3 | NR | NR |
| Muranaka39 | 22 | 16 | Not reached | 9.9 | 0.80 | 6.5 | 3.7 | NR | NR |
| Papneja40 | 33 | 86 | 9 | 9 | 0.88 | 4 | 6 | NR | NR |
| Shahda41 | NR | NR | 11.4–14.4i | 11.3–12.3i | NR | 4.6–6.1i | 5.3–9.4i | NR | NR |
| Wang42 | 87 | 92 | 10.5 (10.0) | 14.1 (9.4) | 0.09 | 8.5 (8.3) | 8.4 (6.6) | NR | NR |
| Franco43 | 49 | 87 | 13 | 13 | NR | NR | NR | NR | NR |
| Helen44 | NR | NR | NR (5.5) | NR (8.8) | NR | NR | NR | NR | NR |
| Kudlovich45 | 21 | 52 | 7.6 (NR) | 8.8 (NR) | NR | NR | NR | NR | NR |
| Tahara46 | 15 | 12 | Not reached (9.8) | 9.7 (9.7) | 0.44 (0.54) | Not reached | 8.8 | NR | NR |
| Terashima47 | 20 | 47 | 9.9 | 10.3 | NR | NR | NR | NR | NR |
| Hegewisch-Becker48 | 489 | 284 | 9.1 | 11.3 | NR | 5.6 | 6.3 | NR | NR |
| Total | 2619 | 2618 | |||||||
1L, first line; aPC, advanced pancreatic cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; FFX, FOLFIRINOX; mPC, metastatic pancreatic cancer; nab-P/G, nab-paclitaxel/gemcitabine; NR, not reported; OS, overall survival; PFS, progression-free survival; TTF, time to treatment failure.
Reported as database persistence, a proxy for OS.
Reported as time to discontinuation.
Modified FFX.
For patients with ECOG PS 0 or 1, median OS was 12.1 and 11.4 months in nab-P/G and FFX groups, respectively
(p = 0.68).
For patients with ECOG PS 0 or 1, median TTF was 4.2 and 4.3 months in nab-P/G and FFX groups, respectively.
59% of patients received modified FFX. The OS and PFS were reported to be statistically similar between FFX and mFFX groups.
For patients with ECOG PS 0 or 1, median OS was 14.1 and 13.7 months in nab-P/G and FFX groups, respectively.
aPC includes mPC. The number in parentheses is the number of patients with mPC.
Biomarker study observing homologous recombination deficiency low versus high in each treatment regimen with data presented here as a range.